fluoride [18F] thretide

Fluoride [18F] thretide (also known as LNC1007) is a radiopharmaceutical diagnostic imaging agent developed by Shanghai Lannacheng Biotechnology, a subsidiary of Dongcheng Pharmaceutical. It consists of a peptide-based ligand, thretide, which exhibits high affinity for prostate-specific membrane antigen (PSMA), labeled with the positron-emitting radioisotope fluorine-18 ([18F]). PSMA is a transmembrane protein that is significantly overexpressed in prostate cancer cells compared to normal tissues, making it an ideal target for molecular imaging. Upon intravenous administration, the tracer binds to PSMA-expressing cells, enabling the detection and localization of primary and metastatic prostate cancer lesions using PET/CT or PET/MRI. It is primarily being developed for the evaluation of patients with biochemical recurrence of prostate cancer to identify the site and extent of disease when conventional imaging is negative or equivocal.

Other names

[18F]thretide18F-LNC1007氟[18F]思睿肽注射液